14 results about "Damage dna" patented technology

The curcumin-coupled copper-gold bimetallic nanoszyme AuCu-Cur prepared by the application can remove ROS and relieve oxidative stress, prevent further damage to DNA, and introduce human umbilical cord mesenchymal stem cell-derived extracellular vesicles (hUCMSC-EVs) to improve the bioavailability. In the system, curcumin can repair damaged DNA by promoting the expression of NEIL3. In addition, the vesicles themselves are rich in various tissue repair-related proteins and RNAs, which can promote DNA replication of notochordal cells (NPCs), reverse the aging state and stimulate extracellular matrix synthesis. In the IVDD model induced by rat tail vertebra puncture, we confirmed that the material has strong antioxidant and DNA repair capacity and can effectively delay cell aging, thereby relieving the progression of IVDD. Compared with existing intervertebral disc biomaterial treatments, the present scheme can realize continuous DNA repair, which is an active, multi-target repair program that not only interrupts the vicious cycle of intervertebral disc degeneration but also promotes tissue transformation to regeneration.

[Problem] To provide a composition for a supplement, medicine, food or drink, feed, or similar that is capable of repairing damaged DNA. [Solution] This damaged DNA repairing composition that is characterized by including GABA as an active ingredient can be used as a highly safe supplement, medicine, food or drink, or feed, for anti-aging or health maintenance.

The invention discloses an azide modified platinum radiotherapy sensitizer as well as a preparation method and application thereof. The azide modified platinum radiotherapy sensitizer is an azide modified platinum complex, comprises a cis platinum complex and a trans platinum complex, and is characterized in that the structure of the azide modified platinum radiotherapy sensitizer is shown in the specification; in the formula I, R1 is cyclohexylamine or 2-methylpyridine; in the formula II, R2 is ammonia molecules or pyridine. The azide modified platinum radiotherapy sensitizer can generate a platinum-nitrogen-bin free radical under the irradiation of X rays, and by utilizing a nitrogen transfer reaction in organic chemistry, the platinum-nitrogen-bin free radical generated after the compound is irradiated by rays can be covalently coupled with some DNA (Deoxyribose Nucleic Acid) or protein, so that the sensitivity of the radiotherapy sensitizer is improved. The radiotherapy sensitization effect in tumor radiotherapy is achieved by directly damaging DNA and hindering DNA repair.

The present disclosure describes a method of treating a dsbNETs-associated pathology or con- dition in a subject in need thereof, comprising administering a therapeutically effective amount of a dsbNETs modulator in the subject, wherein dsbNETs repair or misrepair damaged DNA or wherein excessively induced or persistent dsbNETs trigger DNA damage.

The invention relates to the field of protein enrichment, separation and detection, and discloses a probe for capturing response protein of drug damage DNA, the probe comprises the following elements connected in series: (nuclear localization signal-BRD2) n-biotin ligase, and n is an integer from 1 to 4. The probe provided by the invention is good in affinity, the quantity of the response protein for capturing the drug damage DNA can be increased, and the specificity of the response protein for capturing the drug damage DNA can also be considered. The method for capturing the response protein of the drug-damaged DNA is simple, convenient and rapid, can be used for capturing and identifying the response protein in any drug cells which cause DNA damage through covalent bond or coordination bond combination, and also provides a new idea for capturing the response protein of the drug-damaged DNA.

The invention discloses an electrochemical method for detecting DNA (deoxyribonucleic acid) damage based on a CRISPR-Cas12a (clustered regularly interspaced short palindromic repeats-associated 12a) system. Normal DNA can activate the activity of the CRISPR-Cas12a compound, so that the DNA probe fixed on the surface of the electrode is cut. The cut DNA probe cannot be subjected to HCR reaction in the presence of hairpin DNA H1 and H2, so that a relatively small electrochemical signal of methylene blue is generated; the damaged DNA cannot completely activate the activity of the CRISPR-Cas12a compound, at the moment, the uncut DNA probe induces HCR and generates longer double-stranded DNA in the presence of hairpin DNA H1 and H2, and a large number of methylene blue molecules are combined with the double-stranded DNA, so that a stronger electrochemical signal is generated. The damage degree of the DNA corresponds to the light damage level of the DNA, the electrochemical signal of the methylene blue and the light damage level of the DNA are in a linear relation within the range of 0.021-0.42 kJ m <-2 >, and the lowest detection limit is 0.0088 kJ m <-2 >.

The invention discloses a platinum anti-tumor conjugate and a preparation method and application thereof.The conjugate is reduced into a bivalent platinum drug and an LOXL2 inhibitor in tumor cells, the bivalent platinum drug not only can directly damage DNA and promote cell apoptosis, but also can induce ICD and activate T cells; the LOXL2 inhibitor further promotes immune infiltration of tumor tissues by degrading collagenous fibers and softening rigid ECM (extracellular matrix) of tumors, and the LOXL2 inhibitor and the LOXL2 inhibitor cooperatively kill tumor cells.

The invention relates to an immunomodulatory peptide Puerein and application thereof, and belongs to the field of biomedicine. The immunomodulatory peptide Puerein is a polypeptide coded by a defensive peptide gene of a special species Pu'er pan tree frog in China, the molecular weight is 1486.7 Dalton, the isoelectric point is 12.58, and the amino acid sequence of the immunomodulatory peptide Puerein is as shown in SEQ ID NO: 2. The gene GenBank access No.PQ862905 for coding the precursor of the immunomodulatory peptide Puerein is composed of 592 nucleotide sequences, and the nucleotide sequence of the gene GenBank access No.PQ862905 is as shown in SEQ ID NO: 1; wherein the 399th to 435th nucleotides are coding genes of the mature Pu'er ubiquitous frog multifunctional immunomodulatory peptide Puerein. The invention further discloses application of the Pu'er pan-tree frog immunomodulatory peptide Puerein in preparation of anti-oxidation, damaged DNA (deoxyribonucleic acid) removal and skin light damage resistance. The composition has the beneficial effects that the composition has a relatively strong skin light injury resisting effect on the skin and can remarkably inhibit the occurrence of skin light injury.

Provided herein are combination therapies comprising an epoxytigliane compound (for example, tigilanol tiglate) and either irradiation or a chemotherapeutic agent that is i) a chemotherapeutic agent that damages DNA (for example, cisplatin), or ii) a chemotherapeutic agent that inhibits tumour-associated host-derived cells that support the growth and / or invasion of tumour cells (for example, 5-fluoruracil, or doxorubicin). Pharmaceutical compositions and kits containing epoxytigliane compounds and the chemotherapeutic agents are also provided.

The present disclosure describes a method of treating a dsbNETs-associated pathology or con- dition in a subject in need thereof, comprising administering a therapeutically effective amount of a dsbNETs modulator in the subject, wherein dsbNETs repair or misrepair damaged DNA or wherein excessively induced or persistent dsbNETs trigger DNA damage.

The present invention relates to a gene expression regulation optimization technology based on a target DNA recognition ultra-small molecular module, and relates to an ultra-small eCWCas12f-VPR system optimized through engineering of a CRISPR-Cas module, linking of activation domains, and various combinations of linkers and NLS sequences. It has been identified that effective and target-specific gene expression regulation superior to that of a conventional CRISPRa system can be achieved and the accuracy of the gene expression regulation is remarkably excellent. In particular, unlike a conventional CRISPR gene scissors technology, the system of the present invention can accurately regulate the expression of a target gene without cutting or damaging DNA, and thus is relatively safe and optimized for application in a gene therapy method, thereby exerting a great impact, and, due to the characteristics of ultra-small size, enables all genes to be loaded in a single vector (all-in-one), and thus can be effectively used as an excellent novel gene editing technology that compensates for the disadvantages of a conventional gene editing technology.

The application discloses an electrochemical method for detecting DNA damage based on a CRISPR-Cas12a system. Normal DNA can activate the activity of the CRISPR-Cas12a complex, resulting in the cutting of the DNA probe fixed on the electrode surface. The cut DNA probe cannot undergo HCR reaction in the presence of hairpin DNA H1 and H2, thereby generating a smaller electrochemical signal of methylene blue; damaged DNA cannot completely activate the activity of the CRISPR-Cas12a complex, at this time, the uncut DNA probe induces HCR in the presence of hairpin DNA H1 and H2 and generates longer double-stranded DNA, a large number of methylene blue molecules are combined with the double-stranded DNA, thereby generating a stronger electrochemical signal. The damage degree of DNA corresponds to the light damage level thereof, the electrochemical signal of methylene blue and the light damage level of DNA are in a linear relationship in the range of 0.021-0.42 kJ m ‑2 , and the lowest detection limit is 0.0088 kJ m ‑2 .

A drug and a health food for suppressing gene mutations using nucleic acids and RNA. The drug or the health food contains a yeast extract and one or more components derived from a plant, fish, and a dairy product. The yeast extract is present as an active ingredient and particularly contains the RNA as an active ingredient. It does not inhibit DNA damage, but promotes an action of repairing damaged DNA or promotes an action of killing cells containing damaged DNA to suppress gene mutations.

The invention relates to the technical field of biological medicines, in particular to tumor treatment and prognosis application of Ser27 phosphorylated METTL1 protein, and particularly relates to application of a marker detection reagent comprising a reagent for detecting METTL1Ser27 phosphorylation level in preparation of tumor chemoradiotherapy prognosis products. The invention relates to application of a reagent for inhibiting or reducing the phosphorylation level of METTL1Ser27 in preparation of tumor treatment drugs, and a tumor chemoradiotherapy prognosis evaluation system and device based on the phosphorylation level of METTL1Ser27. The invention finds that the phosphorylation level of METTL1Ser27 is negatively correlated with tumor chemoradiotherapy prognosis, the chemoradiotherapy tolerance of tumors can be accurately reflected by detecting the level, and individualized treatment is facilitated; by inhibiting METTL1Ser27 phosphorylation, a chromatin structure can be opened, DNA damage can be enhanced, the radiotherapy and chemotherapy treatment effect can be improved, and the chemotherapy effect can be remarkably improved by combining the METTL1Ser27 phosphorylation with a second effective component for damaging DNA.